Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015674 (chronic fatigue syndrome)
 2,978 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This clinical trial was designed to evaluate the efficacy, safety and patient tolerance of cefoxitin (CFS) in 46 patients who were admitted to the hospitals from June 1983 to April 1984. The daily doses of CFX for 34 patients (ages ranged from 6 to 75 years old) were 2 to 8 g to prevent the infections and for 12 patients (ages ranged from 55 to 81 years old) were 2 to 6 g to treat the infections by intravenous drip infusion 1 or 3 times a day in divided doses. The following results were obtained. All of 34 patients with intracranial operation who received CFX for prevention of postoperative infections showed good results. Of 12 patients with postoperative pneumonia, infections of urinary tract and late meningitis, 11 patients showed good results. One patient was discontinued on the 3 days because of the drug eruption which improved 3 days after. The side effect was noted in only 1 patient. This was eruption which improved 3 days after the stop of the administration. The influences to the laboratory data due to CFX were not recognized. The results of this study demonstrated that CFX was an excellent drug for the prevention and treatment of the postoperative infections in the neurosurgical field because of high efficacy rate and safety.
 ...
PMID:[Clinical studies on cefoxitin in the prevention of postoperative infections and the treatment of postoperative pulmonary and urinary tract infections]. 404 78

In vitro activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections were investigated by dilution method using MIC 2000 (Dynatec) during July to October in 1982. The summarized results are as follows: PMPC and CCL have showed potent activities against E coli among the oral antimicrobial agents. PMPC and CCL at 3.13 micrograms/ml inhibited 90% of E. coli tested. CTM, CTX, CZX, CMX and LMOX at concentrations of 0.39 microgram/ml or less among the parenteral antimicrobial agents inhibited 90% of E. coli tested. The value of MIC90 (concentration at which 90% of isolates are inhibited) against K. pneumoniae results in the resistant range for ABPC, NA, CEX, CCL and ST. Among the parenteral cephems, CMX seemed most effective against K. pneumoniae tested. C. freundii seemed generally low susceptible to antimicrobial agents tested. Among the oral agents, PMPC, PPA and ST have showed moderate activity against C. freundii. Among the parenteral agents, CMX and LMOX also showed moderate activity against C. freundii, inhibiting 50% of the strains tested at 6.25 micrograms/ml. Among the oral agents, PMPC showed the most potent activity against E. cloacae. E. cloacae tested were highly resistant to the first and second generation cephems. Among the third generation, CMX seemed the most potent activity against E. cloacae isolated. However, CMX concentration of 1.56 micrograms/ml was necessary to inhibit 50% of tested E. cloacae. P. mirabilis tested was resistant to all oral antimicrobial agents except CCL and ST. The value of MIC90 of the first and second generation cephems against P. mirabilis results in the moderately susceptible range (6.25-25 micrograms/ml). The third generation seemed most effective against P. mirabilis tested. PMPC, NA, PPA and ST concentrations of 0.78-1.56 micrograms/ml were necessary to inhibit 50% of tested P. vulgaris. CEZ and CTM, seemed less potent activity than CFX and CMZ against P. vulgaris. CTX, CZX, CMX and LMOX except CPZ have showed potent activities against P. vulgaris, these at 0.1 micrograms/ml or less inhibited 50% of P. vulgaris tested. P. aeruginosa has been resistant to the third generation cephems except CPZ, but TOB, GM, AMK, CFS, PIPC and CPZ have showed high activities against P. aeruginosa, inhibiting 50% of the strains tested at 0.39-6.25 micrograms/ml. The oral antimicrobial agents, and first and second generation cephems had not showed significant activity against S. marcescens. And strains of S. marcescens were relatively susceptible to the third generation cephems.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1982). I. Susceptibility distribution]. 643 64

Background: Small-colony variants of methicillin-resistant Staphylococcus aureus (SCV-MRSA) recently were described as slow-growing, thymidine-dependent strains; typically, SCV-MRSA were isolated from patients receiving sulfamethoxazole-trimethoprim, but detection of these strains frequently was delayed because of their small colony size and slow growth. Bacteremia cases due to SCV-MRSA sometimes become lethal when the initiation of treatment with intravenous anti-methicillin-resistant Staphylococcus aureus (MRSA) drugs starts too late. Methods: Here, we evaluated the use of general MRSA-specific agar plates in Japan, including MS-CFX, X-MRSA, and CHROMagar, for the efficient detection of SCV-MRSA, including the comparative detection efficiencies of these media for stock strains and clinical isolates. Results: Among the three MRSA-specific agar plates that were tested, X-MRSA and CHROMagar showed similar detection efficiencies for both 24 and 48 hrs culturing; in contrast, MS-CFS did not permit the detection of SCV-MRSA in stock strains. For clinical isolates of SCV-MRSA, X-MRSA plates permitted detection of the smallest and slowest-growing colonies of SCV-MRSA at 48 hrs of culturing; in contrast, CHROMagar and MS-CFX sometimes did not identify SCV-MRSA at 24 and 48 hrs. Conclusion: Optimization of media and incubation times will be necessary for efficient identification for SCV-MRSA, which would prevent delays in diagnosis and treatment with anti-MRSA drugs.
 ...
PMID:Evaluation of agar culture plates to efficiently identify small colony variants of methicillin-resistant Staphylococcus aureus. 3141 91